RESUMO
BACKGROUND: Atopic dermatitis (AD) is driven by the interplay between a dysfunctional epidermal barrier and a skewed cutaneous immune dysregulation. As part of the complex skin barrier dysfunction, abnormalities in lipid organization and microbiome composition have been described. We set out to systematically investigate the composition of the stratum corneum lipidome, skin microbiome and skin physiology parameters at three different body sites in patients with AD and healthy volunteers. METHODS: We analysed tape strips from different body areas obtained from 10 adults with AD and 10 healthy volunteers matched for FLG mutation status for 361 skin lipid species using the Metabolon mass spectrometry platform. 16S rRNA data were available from all probands. RESULTS: Our study showed that the lipid composition differs significantly between body sites and between AD patients and healthy individuals. Ceramide species NS was significantly higher in AD patients compared to healthy volunteers and was also higher in AD patients with a FLG mutation compared to AD patients without a FLG mutation. The correlation analysis of skin lipid alterations with the microbiome showed that Staphylococcus colonization in AD is positively correlated with ceramide subspecies AS, ADS, NS and NDS. CONCLUSION: This is the first study to reveal site-specific lipid alterations and correlations with the skin microbiome in AD.
Assuntos
Ceramidas/metabolismo , Ésteres do Colesterol/metabolismo , Dermatite Atópica/microbiologia , Ácidos Graxos não Esterificados/metabolismo , Microbiota , Adulto , Feminino , Humanos , Lipidômica , Masculino , Pele/microbiologiaRESUMO
BACKGROUND: The ultimate goal of wound healing following minor injury is to form a tissue regenerate that has functionality and visual appearance as close to the original skin as possible. The body's physiological response to any wound is traditionally characterised by three distinct steps: inflammation, proliferation and remodelling. SUMMARY: New insights suggest that the three phases overlap (and even occur in parallel) in both time and space in the wound, necessitating a clinical approach that targets each stage simultaneously to ensure rapid repair and wound closure without further complications. Ingredients that exhibit activity across each of the three phases, such as dexpanthenol, are of value in the context of minor wound care and scar management. Key Messages: In addition to treatment and ingredient selection, it is also important to consider broader clinical best practices and self-care options that can be used to optimise the management of minor wounds. An individualised approach that can account for a patient's unique requirements and preferences is critical in achieving effective wound recovery.
Assuntos
Pele , Cicatrização , Movimento Celular/efeitos dos fármacos , Movimento Celular/fisiologia , Proliferação de Células/efeitos dos fármacos , Proliferação de Células/fisiologia , Cicatriz/etiologia , Cicatriz/fisiopatologia , Cicatriz/psicologia , Cicatriz/terapia , Fármacos Dermatológicos/administração & dosagem , Humanos , Concentração de Íons de Hidrogênio , Inflamação/tratamento farmacológico , Inflamação/fisiopatologia , Ácido Pantotênico/administração & dosagem , Ácido Pantotênico/análogos & derivados , Espécies Reativas de Oxigênio , Pele/efeitos dos fármacos , Pele/lesões , Pele/microbiologia , Pele/fisiopatologia , Fenômenos Fisiológicos da Pele/efeitos dos fármacos , Cicatrização/efeitos dos fármacos , Cicatrização/fisiologia , Ferimentos e Lesões/fisiopatologia , Ferimentos e Lesões/terapiaRESUMO
Endocannabinoids (ECs) are important regulators of cell signalling. Cannabinoid receptors are involved in keratinocyte proliferation/differentiation. Elevation of the endogenous cannabinoid tone leads to strong anti-inflammatory effects. Here, we explored the influence of endocannabinoid system (ECS) modulators on skin permeability barrier repair, epidermal proliferation, differentiation and inflammation in hairless mice. We used WOBE440, a selective fatty acid amide hydrolase (FAAH) inhibitor, WOL067-531, an inhibitor of endocannabinoid reuptake with no relevant FAAH activity, which both signal via cannabinoid receptor-1 and cannabinoid receptor-2 (CB-1R and CB-2R) and compared them to WOBE15 which signals via CB-2R. Barrier disruption and skin irritation were induced by tape stripping or by sodium dodecyl sulphate (SDS) patch testing. Immediately after barrier disruption, 30 µL of 0.5% WOBE440, WOL067-531 and WOBE15 solutions or the vehicle was applied topically. Barrier repair was monitored by transepidermal water loss at 1.5, 3, 5 and 7 hours. We found that barrier repair was significantly delayed by WOL067-531. A tendency for a delay was noticed for WOBE440, whereas for WOBE15, no effect was observed. Immunohistology showed that the tape-stripping-induced increase in epidermal proliferation and filaggrin expression was significantly reduced by topical applications of WOL067-531 and WOBE440, but not by WOBE15. Also, the SDS-induced inflammation, as determined by the number of inflammatory cells, was reduced by WOL067-531 and WOBE440. In summary, we showed that WOL067-531 exhibits a significant effect on skin barrier repair, epidermal proliferation/differentiation and inflammation.
Assuntos
Endocanabinoides/fisiologia , Absorção Cutânea/efeitos dos fármacos , Amidoidrolases/antagonistas & inibidores , Animais , Benzoxazóis/farmacologia , Água Corporal/metabolismo , Endocanabinoides/antagonistas & inibidores , Epiderme/efeitos dos fármacos , Epiderme/lesões , Epiderme/metabolismo , Epiderme/patologia , Proteínas Filagrinas , Proteínas de Filamentos Intermediários/biossíntese , Camundongos , Camundongos Pelados , Testes do Emplastro , Receptor CB1 de Canabinoide/antagonistas & inibidores , Receptor CB2 de Canabinoide/antagonistas & inibidores , Dodecilsulfato de Sódio/toxicidade , Subpopulações de Linfócitos T/imunologiaRESUMO
Barrier damage, dry skin and itch are intricately linked and form the basis of many common skin diseases. Damage from environmental insults, or genetic or inflammatory causes, can impair the skin barrier, resulting in an increase in transepidermal water loss and activation of itch-associated nerve fibres. The itch-scratch cycle can perpetuate skin barrier damage and itch. Topical therapeutic strategies are utilised to overcome dry skin and itch, primarily in the form of emollients. Recent advances in our understanding of the mechanisms underlying itch have enabled the development of new topical therapies, which may be incorporated into existing treatment regimes. Ultimately, treatment of dry skin and itch must be highly tailored to the individual according to their needs.
Assuntos
Emolientes/uso terapêutico , Prurido/tratamento farmacológico , Dermatopatias/fisiopatologia , Pele/metabolismo , Administração Tópica , Feminino , Previsões , Alemanha , Humanos , Masculino , Prurido/fisiopatologia , Pele/efeitos dos fármacos , Absorção Cutânea/efeitos dos fármacos , Absorção Cutânea/fisiologia , Dermatopatias/tratamento farmacológicoRESUMO
The pH of the skin is tightly regulated by endogenous buffering systems. We examined the influence of buffers of different pH and composition on skin barrier repair, pH, inflammation, and epidermal thickness/proliferation/differentiation. After tape-stripping in hairless mice buffers with pH 4-7 were applied in patch test chambers. After removal of the chambers, skin pH and transepidermal water loss (TEWL) were monitored for 24 h, and biopsies were taken for histology/immunohistology. Hairless mice showed a basal skin pH of about 5.8. Following barrier disruption and application of water, the pH increased by 0.6 units; increase in pH was reduced by the pH 4 glycolate buffer, unchanged by pH 4 citrate and pH 5.5 buffers, and even increased by the pH 7 buffer. pH 5.5, pH 4 citrate, and pH 4 glycolate buffers led to a slight, while the pH 7 buffer led to a significant increase in TEWL after barrier disruption compared to water. The pH 7 buffers led to a significant increase in epidermal thickness/proliferation/differentiation and inflammation after barrier disruption, whereas buffers with pH 4 and 5.5 caused a slight increase. In conclusion, only the pH 4 glycolate buffer significantly reduced the skin barrier disruption-related increase in skin pH. This was accompanied by only slight increase in epidermal thickness and inflammation compared to water. Application of the pH 7 buffer led to a significant increase in the skin pH, TEWL, epidermal thickness, and inflammation. The results are important for the formulation of topical products for effective acidification in pathological skin conditions.
Assuntos
Pele/química , Animais , Soluções Tampão , Proliferação de Células , Citocinas/metabolismo , Concentração de Íons de Hidrogênio , Inflamação/metabolismo , Masculino , Camundongos Pelados , Pele/anatomia & histologia , Pele/citologia , Pele/metabolismo , Perda Insensível de ÁguaRESUMO
Eruptive pseudoangiomatosis is a distinct exanthem thought to be caused by viruses. The usual rash configu-ration is erythematous papules and macules. An association with echovirus infection has been reported. We present here one adult and one child with this exanthem, supported by clinical, histopathological, and immunohistochemical findings. Both patients presented with prodromal symptoms, widespread angioma-like macules in annular configuration, blanchable telangiectasia, followed by spontaneous remission in 6-8 weeks. Lesional histopathology of the adult patient revealed dilated dermal blood vessels and lymphohistiocytic infiltrates predominated by CD4+ lymphocytes with a 5:1 ratio of CD4:CD8 lymphocytes. No B cells or CD56+ natural killer cells were found. Serology of both patients revealed evidence of active infections by adenoviruses, and a range of other viruses were excluded. We believe that these 2 patients manifested annular eruptive pseudoangio-matosis, a novel variant of the rash with a probable adenovirus association that has not yet been reported.
Assuntos
Infecções por Adenoviridae/virologia , Adenoviridae/patogenicidade , Angiomatose/virologia , Exantema/virologia , Pele/virologia , Adenoviridae/imunologia , Infecções por Adenoviridae/diagnóstico , Infecções por Adenoviridae/imunologia , Angiomatose/diagnóstico , Angiomatose/imunologia , Biópsia , Pré-Escolar , Exantema/diagnóstico , Exantema/imunologia , Humanos , Imuno-Histoquímica , Masculino , Remissão Espontânea , Pele/imunologia , Pele/patologia , Fatores de Tempo , Adulto JovemRESUMO
The aim of the study was to investigate the expression of Toll-like receptors (TLRs) 2 and 4 on keratinocytes in atopic dermatitis, contact dermatitis, and psoriasis by PCR and by immunohistochemistry including confocal microscopy. Confocal microscopy revealed a granular intra-cellular expression pattern for TLR 2 and a homogenous intra-cellular expression pattern for TLR 4 in normal and diseased skin. TLR 2 was constitutively expressed in the suprabasal layers in normal skin, but limited to the basal epidermis in diseased skin. TLR 4 expression was concentrated to the basal layers in normal skin, whereas it was pronounced in upper layers in diseased skin. The shift in the TLR expression may be related to the disturbed skin barrier and a need for enhanced immune surveillance because of invading microbes. Also, there must be a balance between sufficient immune response and overstimulation.
Assuntos
Dermatite Atópica/metabolismo , Dermatite de Contato/metabolismo , Psoríase/metabolismo , Pele/metabolismo , Receptor 2 Toll-Like/metabolismo , Receptor 4 Toll-Like/metabolismo , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Humanos , Imunidade Inata , Queratinócitos/citologia , Queratinócitos/metabolismo , Microscopia ConfocalRESUMO
ß-Defensins are antimicrobial peptides of the innate immune system produced in the skin by various stimuli, including proinflammatory cytokines, bacterial infection, and exposure to UV radiation (UVR). In this study we demonstrate that the UVR-inducible antimicrobial peptide murine ß-defensin-14 (mBD-14) switches CD4(+)CD25(-) T cells into a regulatory phenotype by inducing the expression of specific markers like Foxp3 and CTLA-4. This is functionally relevant because mBD-14-treated T cells inhibit sensitization upon adoptive transfer into naive C57BL/6 mice. Accordingly, injection of mBD-14, comparable to UVR, suppresses the induction of contact hypersensitivity and induces Ag-specific regulatory T cells (Tregs). Further evidence for the ability of mBD-14 to induce Foxp3(+) T cells is provided using DEREG (depletion of Tregs) mice in which Foxp3-expressing cells can be depleted by injecting diphtheria toxin. mBD-14 does not suppress sensitization in IL-10 knockout mice, suggesting involvement of IL-10 in mBD-14-mediated immunosuppression. However, unlike UVR, mBD-14 does not appear to mediate its immunosuppressive effects by affecting dendritic cells. Accordingly, UVR-induced immunosuppression is not abrogated in mBD-14 knockout mice. Together, these data suggest that mBD-14, like UVR, has the capacity to induce Tregs but does not appear to play a major role in UVR-induced immunosuppression. Through this capacity, mBD-14 may protect the host from microbial attacks on the one hand, but tame T cell-driven reactions on the other hand, thereby enabling an antimicrobial defense without collateral damage by the adaptive immune system.
Assuntos
Diferenciação Celular/imunologia , Linfócitos T Reguladores/citologia , Linfócitos T Reguladores/imunologia , beta-Defensinas/administração & dosagem , beta-Defensinas/fisiologia , Transferência Adotiva , Animais , Antígeno CTLA-4/biossíntese , Diferenciação Celular/genética , Diferenciação Celular/efeitos da radiação , Dinitrofluorbenzeno/administração & dosagem , Feminino , Fatores de Transcrição Forkhead/biossíntese , Imunofenotipagem , Injeções Intravenosas , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Neuropilinas/biossíntese , Linfócitos T Reguladores/efeitos da radiação , Raios Ultravioleta , beta-Defensinas/deficiênciaRESUMO
In dry skin (DS), skin-barrier function is easily disturbed and moisturizing factors in the stratum corneum are reduced. Despite being a common condition, DS is often overlooked in patients with advanced age or comorbid diseases. In September 2022, specialists in dermatology and skin care met to discuss unmet needs and management of patients with DS with existing medical conditions or DS induced by ongoing pharmacological treatments. There was consensus about the need to improve the current understanding and management of DS in patients with comorbidities, including type 2 diabetes, chronic kidney disease, radiodermatitis, and photodamaged skin. Clinical guidance related to optimal treatment of DS in patients with advanced age or comorbid diseases is needed. Dexpanthenol-containing emollients have been shown to provide rapid relief from the symptoms and clinical signs of skin inflammation and are well-tolerated and effective in terms of moisturizing and soothing DS and maintaining skin-barrier function. Thus, dexpanthenol-containing emollients may play an important role in future management of DS. Further research is needed to elucidate the efficacy of dexpanthenol across the spectrum of DS, irrespective of comorbidity status or age.
Assuntos
Diabetes Mellitus Tipo 2 , Ictiose , Ácido Pantotênico/análogos & derivados , Humanos , Emolientes/uso terapêutico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Ictiose/tratamento farmacológico , Veículos Farmacêuticos , ComorbidadeRESUMO
Patients with atopic dermatitis (AD) have an epidermal barrier dysfunction, which allows invasion of allergens to occur. Stratum corneum skin barrier is formed by corneocytes and extracellular lipids extruded from the epidermal lamellar bodies. In a controlled, randomized, double-blinded, right-left comparison study we investigated the effect of pimecrolimus (PIM) cream compared with triamcinolone acetonide cream (TA) on the skin barrier in 15 patients with symmetrical elbow lesions of AD. In punch biopsies, before and after treatment, skin lipid bilayer and lamellar body structure were examined by transmission electron microscopy (TEM). Partial Eczema Area and Severity Index (pEASi), stratum corneum hydration, and transepidermal water loss (TEWL) were monitored on days 1, 8 and 22. The pEASi was significantly more improved with TA compared with PIM, whereas stratum corneum hydration was slightly more improved after treatment with PIM. The TEM revealed a strong reduction in lamellar bodies in lesional skin of AD; only 32% of the lamellar bodies were normal. A significantly higher number of normal lamellar bodies was found after 3 weeks of treatment with PIM (58%; p < 0.005). An increase in lamellar bodies also occurred with TA treatment (46%; p < 0.05); however, significantly less than with PIM (p < 0.05). Clinical score and TEWL were more improved after treatment with TA, whereas the lamellar bodies were more normal after treatment with PIM.
Assuntos
Dermatite Atópica/tratamento farmacológico , Fármacos Dermatológicos/administração & dosagem , Epiderme/efeitos dos fármacos , Glucocorticoides/administração & dosagem , Tacrolimo/análogos & derivados , Triancinolona Acetonida/administração & dosagem , Administração Cutânea , Adulto , Biópsia , Dermatite Atópica/diagnóstico , Dermatite Atópica/metabolismo , Método Duplo-Cego , Epiderme/metabolismo , Epiderme/ultraestrutura , Feminino , Alemanha , Humanos , Masculino , Microscopia Eletrônica de Transmissão , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Creme para a Pele , Tacrolimo/administração & dosagem , Fatores de Tempo , Resultado do Tratamento , Perda Insensível de Água/efeitos dos fármacos , Adulto JovemRESUMO
BACKGROUND: The skin barrier plays a crucial role in the pathophysiology of atopic dermatitis. The quality of the skin barrier can be assessed using a new semi-quantitative method to measure intercellular lipid lamellae. This procedure was used to evaluate the influence of the topical application of the calcineurin inhibitor tacrolimus 0.1% ointment (Protopic®) versus mometasone furoate cream (Ecural®) on the quality of the skin barrier. PATIENTS AND METHODS: 20 adult patients with active atopic dermatitis (SCORAD 10-63) were included in an open, non-interventional study. Lesions on their forearms were treated twice daily over 10 days with either tacrolimus 0.1% ointment or mometasone furoate cream. At the beginning and the end of the treatment period, SCORAD, TEWL and skin hydration were determined and the intercellular lipids were measured using transmission electron microscopy. RESULTS: The SCORAD improved in both groups nearly to the same extent, whereas TEWL and skin hydration improved significantly only in the tacrolimus group. Using the semi-quantitative analysis of intercellular lipid length per 1,000 nm(2) intercellular space, a twofold increase for mometasone furoate cream and a fourfold increase for tacrolimus 0.1% ointment were determined. CONCLUSIONS: In addition to its known antiinflammatory effect, tacrolimus 0.1% ointment leads also to a measurable increase of the lipids of the skin barrier in patients with atopic dermatitis, exceeding the effect of mometasone furoate cream.
Assuntos
Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/patologia , Epiderme/efeitos dos fármacos , Epiderme/patologia , Pregnadienodiois/administração & dosagem , Absorção Cutânea/efeitos dos fármacos , Tacrolimo/administração & dosagem , Administração Tópica , Adulto , Antialérgicos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Feminino , Humanos , Imunossupressores/administração & dosagem , Masculino , Pessoa de Meia-Idade , Furoato de Mometasona , Pomadas , Creme para a Pele/administração & dosagem , Resultado do TratamentoRESUMO
The S100 fused-type proteins (SFTPs) are thought to be involved in the barrier formation and function of the skin. Mutations in the profilaggrin gene, one of the best investigated members of this family, are known to be the major risk factors for ichthyosis vulgaris and atopic dermatitis. Recently, we identified human filaggrin-2 as a new member of the SFTP family. To achieve further insight into its function, here the murine filaggrin-2 was analysed as a possible orthologue. The 5' and 3' ends of the mouse filaggrin-2 cDNA of the BALB/c strain were sequenced and confirmed an organization typical for SFTPs. Murine filaggrin-2 showed an expression pattern mainly in keratinizing epithelia in the upper cell layers on both mRNA and protein levels. The expression in cultured mouse keratinocytes was increased upon elevated Ca(2+) levels. Immunoblotting experiments indicated an intraepidermal processing of the 250-kDa full-length protein. In metabolically (essential fatty acid-deficient diet) induced skin barrier dysfunction, filaggrin-2 expression was significantly reduced, whereas filaggrin expression was up-regulated. In contrast, mechanical barrier disruption with acetone treatment did not affect filaggrin-2 mRNA expression. These results suggest that filaggrin-2 may contribute to epidermal barrier function and its regulation differs, at least in parts, from that of filaggrin.
Assuntos
Epiderme/fisiologia , Proteínas de Filamentos Intermediários/genética , Proteínas de Filamentos Intermediários/fisiologia , Dermatopatias/genética , Dermatopatias/fisiopatologia , Animais , Sequência de Bases , Diferenciação Celular , Células Cultivadas , Primers do DNA/genética , DNA Complementar/genética , Dermatite Atópica/etiologia , Regulação para Baixo , Ácidos Graxos Essenciais/administração & dosagem , Ácidos Graxos Essenciais/deficiência , Proteínas Filagrinas , Humanos , Ictiose Vulgar/etiologia , Proteínas de Filamentos Intermediários/química , Queratinócitos/citologia , Queratinócitos/metabolismo , Camundongos , Camundongos Pelados , Camundongos Endogâmicos BALB C , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Proteínas S100/genética , Dermatopatias/etiologiaRESUMO
BACKGROUND: A side effect of radiotherapy for breast cancer is acute radiodermatitis. It is a common practice to keep irradiated skin dry on account of data from the 1950s that suggested this regimen limits dermatitis. However, severe dryness of the skin induced by irradiation results in itching and discomfort. Dry skin is characterized by scaliness, epidermal barrier dysfunction, and reduced stratum corneum hydration, and these signs and symptoms are reduced by treatment with an emulsion. PATIENTS AND METHODS: We performed a randomized, controlled, open-label study with 66 patients (ITT population), treating the irradiated skin in one group (n = 34) with an oil-in-water emulsion (WO1932), while leaving the other group untreated (n = 32). Clinical scoring (ONS radiation skin reaction scoring, pruritus) and biophysical measurements (stratum corneum hydration and transepidermal water loss (TEWL), as a marker of skin barrier function) were determined at day 1 (directly after termination of the radiation therapy), day 8, and day 47 (± 7). RESULTS: Irradiation increased the ONS score and pruritus, whereas skin hydration and TEWL were reduced. The primary hypothesis that the increase in skin hydration was significantly greater in the emulsion-treated compared to the untreated group as early as after 8 days of treatment could not be confirmed. At the end of the study (day 47 ± 7), however, normalization of stratum corneum hydration was more advanced in the treatment group compared to the untreated group and nearly reached the values of the contralateral healthy breast skin. ONS score and pruritus also revealed an advantage for the emulsion-treated group. TEWL did not show significant changes during emulsion treatment. No adverse events were caused by the treatment regimens CONCLUSION: Treatment of radiodermatitis with an oil-in-water emulsion was well tolerated, enhanced stratum corneum hydration, improved clinical indicators, and provided relief from itching.
Assuntos
Neoplasias da Mama/radioterapia , Fármacos Dermatológicos/uso terapêutico , Emulsões/uso terapêutico , Radiodermite/tratamento farmacológico , Radiodermite/etiologia , Radioterapia/efeitos adversos , Adulto , Fármacos Dermatológicos/farmacologia , Emulsões/farmacologia , Epiderme/efeitos dos fármacos , Feminino , Humanos , Fatores de Tempo , Resultado do TratamentoRESUMO
There is increasing concern about the interaction between infrared radiation (IR) and ultraviolet radiation (UVR) with regard to carcinogenesis because prolonged solar exposure is associated with an increased cumulative load not only of UVR but also of IR. We recently demonstrated that IR-pretreatment reduces UVR-induced apoptosis. As this might support the survival of UVR-damaged cells and thus carcinogenesis, we performed an in vivo photocarcinogenesis study. One group of mice were treated with IR prior to each UVR exposure; additional groups were treated with IR or UVR alone. IR alone did not induce skin cancer. UVR-induced tumor formation was not enhanced in IR-pretreated mice, but, in contrast, seemed to occur with delay. This correlated with a reduction of p53 mutated clones in the skin. However, once developed, tumors in IR-pretreated mice grew faster which was confirmed by their enhanced Ki-67 expression. The enhanced aggressiveness of tumors derived from IR-pretreated mice was associated with a higher prevalence of sarcomas than epithelial tumors. Hence, the impact of IR on UVR-induced carcinogenesis has to be interpreted with caution. Although IR may delay the onset of UVR-induced tumors, it might contribute to a worse outcome by shifting these tumors into a more aggressive phenotype.
Assuntos
Carcinoma de Células Escamosas/etiologia , Raios Infravermelhos/efeitos adversos , Neoplasias Induzidas por Radiação/etiologia , Sarcoma/etiologia , Neoplasias Cutâneas/etiologia , Raios Ultravioleta/efeitos adversos , Animais , Carcinoma de Células Escamosas/patologia , Proliferação de Células , Transformação Celular Neoplásica/efeitos da radiação , Dano ao DNA , Feminino , Genes p53/genética , Estimativa de Kaplan-Meier , Antígeno Ki-67/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Mutação , Neoplasias Induzidas por Radiação/patologia , Sarcoma/patologia , Neoplasias Cutâneas/patologia , Luz Solar/efeitos adversos , Células Tumorais CultivadasRESUMO
It has been suggested that the increased rate of bacterial infection in atopic dermatitis (AD) may be caused by reduced antimicrobial protein (AMP) expression. We were interested whether common treatments in AD affect antimicrobial defense. We investigated the effects of topically applied corticosteroids betamethasone valerate (BV) and triamacinolone acetonide (TA) and those of the calcineurin inhibitor pimecrolimus for 3 weeks on AMP expression in AD. BV and TA treatment in AD led to a significant reduction in AMP expression; protein expression of human beta-defensins (hBD)-2 and hBD-3, psoriasin, RNase 7 and cathelicidin LL-37 was below the level in skin of healthy controls. After pimecrolimus treatment, AMP expression was also reduced but less compared to BV and TA; the expression levels of hBD-2, psoriasin and RNase 7 still remained above the control levels. In essential fatty acid-deficient (EFAD) mice, a model of chronic skin barrier disease with inflammation, expression of the mouse beta-defensins mBD-1, mBD-3 and mBD-14 (orthologues for hBD-1, hBD-2 and hBD-3, respectively), was reduced by both treatments, again more pronounced by BV compared to pimecrolimus. In summary, we found that treatment for AD with corticosteroids in human skin and EFAD mice caused a strong reduction in AMPs; reduction was less with pimecrolimus. This result may explain the clinical observation that prolonged treatment with topical corticosteroids sometimes leads to bacterial infection.
Assuntos
Corticosteroides/efeitos adversos , Peptídeos Catiônicos Antimicrobianos/metabolismo , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/metabolismo , Tacrolimo/análogos & derivados , Animais , Peptídeos Catiônicos Antimicrobianos/genética , Sequência de Bases , Valerato de Betametasona/efeitos adversos , Inibidores de Calcineurina , Estudos de Casos e Controles , Primers do DNA/genética , Dermatite Atópica/complicações , Dermatite Atópica/genética , Modelos Animais de Doenças , Ácidos Graxos Essenciais/deficiência , Expressão Gênica/efeitos dos fármacos , Humanos , Masculino , Camundongos , Camundongos Pelados , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Dermatopatias Bacterianas/etiologia , Tacrolimo/efeitos adversos , Triancinolona Acetonida/efeitos adversos , beta-Defensinas/genética , beta-Defensinas/metabolismoRESUMO
Atopic dermatitis (AD) is a chronic, inflammatory skin disorder characterized by eczematous and pruritic skin lesions. In recent decades, the prevalence of AD has increased worldwide, most notably in developing countries. The enormous progress in our understanding of the complex composition and functions of the epidermal barrier allows for a deeper appreciation of the active role that the skin barrier plays in the initiation and maintenance of skin inflammation. The epidermis forms a physical, chemical, immunological, neuro-sensory, and microbial barrier between the internal and external environment. Not only lesional, but also non-lesional areas of AD skin display many morphological, biochemical and functional differences compared with healthy skin. Supporting this notion, genetic defects affecting structural proteins of the skin barrier, including filaggrin, contribute to an increased risk of AD. There is evidence to suggest that natural environmental allergens and man-made pollutants are associated with an increased likelihood of developing AD. A compromised epidermal barrier predisposes the skin to increased permeability of these compounds. Numerous topical and systemic therapies for AD are currently available or in development; while anti-inflammatory therapy is central to the treatment of AD, some existing and novel therapies also appear to exert beneficial effects on skin barrier function. Further research on the skin barrier, particularly addressing epidermal differentiation and inflammation, lipid metabolism, and the role of bacterial communities for skin barrier function, will likely expand our understanding of the complex etiology of AD and lead to identification of novel targets and the development of new therapies.
Assuntos
Dermatite Atópica/imunologia , Fármacos Dermatológicos/farmacocinética , Epiderme/patologia , Microbiota/imunologia , Diferenciação Celular/efeitos dos fármacos , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/patologia , Fármacos Dermatológicos/uso terapêutico , Desenvolvimento de Medicamentos , Epiderme/efeitos dos fármacos , Epiderme/imunologia , Proteínas Filagrinas , Humanos , Metabolismo dos Lipídeos/efeitos dos fármacos , Metabolismo dos Lipídeos/imunologia , Microbiota/efeitos dos fármacos , Permeabilidade/efeitos dos fármacos , Perda Insensível de Água/efeitos dos fármacos , Perda Insensível de Água/imunologiaRESUMO
BACKGROUND: Genetic defects leading to skin barrier dysfunction were recognized as risk factors for atopic dermatitis (AD). It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. OBJECTIVES: We investigated the effect of 2 common treatments, a calcineurin inhibitor and a corticosteroid, on the skin barrier. METHODS: In a randomized study 15 patients with AD were treated on one upper limb with pimecrolimus and on the other with betamethasone twice daily for 3 weeks. RESULTS: Stratum corneum hydration and transepidermal water loss, a marker of the inside-outside barrier, improved in both groups. Dye penetration, a marker of the outside-inside barrier, was also reduced in both drugs. Electron microscopic evaluation of barrier structure displayed prevalently ordered stratum corneum lipid layers and regular lamellar body extrusion in pimecrolimus-treated skin but inconsistent extracellular lipid bilayers and only partially filled lamellar bodies after betamethasone treatment. Both drugs normalized epidermal differentiation and reduced epidermal hyperproliferation. Betamethasone was superior in reducing clinical symptoms and epidermal proliferation; however, it led to epidermal thinning. CONCLUSION: The present study demonstrates that both betamethasone and pimecrolimus improve clinical and biophysical parameters and epidermal differentiation. Because pimecrolimus improved the epidermal barrier and did not cause atrophy, it might be more suitable for long-term treatment of AD.
RESUMO
BACKGROUND: Genetic defects leading to skin barrier dysfunction were recognized as risk factors for atopic dermatitis (AD). It is essential that drugs applied to patients with AD restore the impaired epidermal barrier to prevent sensitization by environmental allergens. OBJECTIVES: We investigated the effect of 2 common treatments, a calcineurin inhibitor and a corticosteroid, on the skin barrier. METHODS: In a randomized study 15 patients with AD were treated on one upper limb with pimecrolimus and on the other with betamethasone twice daily for 3 weeks. RESULTS: Stratum corneum hydration and transepidermal water loss, a marker of the inside-outside barrier, improved in both groups. Dye penetration, a marker of the outside-inside barrier, was also reduced in both drugs. Electron microscopic evaluation of barrier structure displayed prevalently ordered stratum corneum lipid layers and regular lamellar body extrusion in pimecrolimus-treated skin but inconsistent extracellular lipid bilayers and only partially filled lamellar bodies after betamethasone treatment. Both drugs normalized epidermal differentiation and reduced epidermal hyperproliferation. Betamethasone was superior in reducing clinical symptoms and epidermal proliferation; however, it led to epidermal thinning. CONCLUSION: The present study demonstrates that both betamethasone and pimecrolimus improve clinical and biophysical parameters and epidermal differentiation. Because pimecrolimus improved the epidermal barrier and did not cause atrophy, it might be more suitable for long-term treatment of AD.